CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
for
Diffuse Large B Cell Lymphoma
Location: St Louis MO
Sponsor: Washington University School of Medicine
Sex: All
Age: 18 - 70+
Code: NCT06687772
Phase2, Recruiting
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
for
Relapsed and/or Refractory B-cell Lymphoma
Location: New York NY, Hackensack NJ, Montreal, Norfolk VA,
Sponsor: Kite, A Gilead Company
Sex: All
Age: 18+
Code: NCT04989803
Phase1, Phase2, Recruiting
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
for
HPV-Related Cervical Carcinoma,
Location: Orlando FL, Tampa FL, Tulsa OK
Sponsor: Theravectys S.A.
Sex: All
Age: 18+
Code: NCT06319963
Phase1, Phase2, Recruiting
Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy
for
Lung Neoplasm, Cell Hypoxia
Location: Edmonton
Sponsor: AHS Cancer Control Alberta
Sex: All
Age: 18+
Code: NCT00765986
Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
for
B-Cell Leukemia, Non-Hodgkin's Lymphoma,
Location: Ottawa, Toronto, Calgary, Vancouver
Sponsor: British Columbia Cancer Agency
Sex: All
Age: 1+
Code: NCT06208735
Phase1, Recruiting
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
for
Large B-cell Lymphoma, Relapse
Location: Miami FL
Sponsor: University of Miami
Sex: All
Age: 18+
Code: NCT06919939
Phase2, Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
for
Mantle Cell Lymphoma, B Cell Lymphoma
Location: Boston MA, New Haven CT, New York NY, Paramus NJ,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06742996
Phase3, Recruiting
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel